METHOD OF TREATING THROMBOCYTOPENIA
Invented is a method of treating thrombocytopenia in a human in need thereof which comprises the administration of a therapeutically effective amount of a 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid to such human.
1 . A method of administering the compound: 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino)-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine), wherein the compound is administered once daily and each dose is administered more than four hours from the administration of a medicine or product that contains polyvalent cations.
2 . A method according to claim 1 wherein the compound is administered in an amount selected from: 25 mg, 50 mg and 75 mg, based on the amount of free or unsalted compound.
3 . A method according to claim 1 wherein the polyvalent cation is in a form selected from: antacids, dairy products and mineral supplements.
4 . A method according to claim 1 wherein the polyvalent cation is selected from: iron, calcium, aluminum, magnesium, selenium and zinc.
5 . A method of administering the compound: 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino)-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine), wherein the compound is administered once daily for at least one week and each dose is administered more than four hours from the administration of a medicine or product that contains polyvalent cations.
6 . A method according to claim 5 wherein the compound is administered in an amount selected from: 25 mg, 50 mg and 75 mg, based on the amount of free or unsalted compound.
7 . A method according to claim 5 wherein the polyvalent cation is in a form selected from: antacids, dairy products and mineral supplements.
8 . A method according to claim 5 wherein the polyvalent cation is selected from: iron, calcium, aluminum, magnesium, selenium and zinc.
9 . A method of administering the compound: 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino)-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine), wherein the compound is administered once daily for at least four weeks and each dose is administered more than four hours from the administration of a medicine or product that contains polyvalent cations.
10 . A method according to claim 9 wherein the compound is administered in an amount selected from: 25 mg, 50 mg and 75 mg, based on the amount of free or unsalted compound.
11 . A method according to claim 9 wherein the polyvalent cation is in a form selected from: antacids, dairy products and mineral supplements.
12 . A method according to claim 9 wherein the polyvalent cation is selected from: iron, calcium, aluminum, magnesium, selenium and zinc.